Objectives:
identification and synthesis of some of the functional nanostructure groups;
introduction of the p53 gene sequence inside the nanostructure cavity;
performing in vitro and in vivo biological tests upon hepatic tumors;
| OBJECTIVES |
|
| DESCRIPTION | Hepatocarcinoma represents one of the principal causes of death through cancer worldwide, with an approximate figure of one million deaths per year and a 5 year survival rate of below 5%. The results of the various forms of tratements available are unsatisfactory on a long term period that’s why a new therapeutic strategy is becoming necessary. The possibility of the treatment of this cancer, a disease defined by defective genes, through introduction of a gene which targets this modification, lead to an enormous interest for the gene therapy of the cancer. p53 is a tumor suppressive gene with an important role in the regulation of cell cycle and it is considered that loss of the function of “wild type” of p53 is a promoter of carcinogenesis. The in vitro and in vivo studies had demonstrated that reintroduction and expression of “wild type” p53 in the tumoral cells with mutation of p53 lead to decreased growth of the tumor and induction of apoptosis. One of the limitations of this gene therapy represents the finding of an adequate vector to introduce the “wild type” p53 in the tumoral cells. Restoring the normal activity of antioncogenic p53 causes tumor regression. The reactivation of p53 can lead to apoptosis or can cause reduction in the proliferation respectively senescence of the cell. The NANOGEN project proposes increased efficiency in the treatment of hepatocarcinoma with the help of gene therapy through internalization of p53 in the tumoral hepatic cells by using a nanoparticle vector with an increased affinity to these tumoral cells. |
| RESULTS ESTIMATED |
|
| RESULTS OBTAINED | |
| Other Informations | |
| Attached documents: |